|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for OLR1 |
 Gene summary |
| Basic gene Info. | Gene symbol | OLR1 |
| Gene name | oxidized low density lipoprotein (lectin-like) receptor 1 | |
| Synonyms | CLEC8A|LOX1|LOXIN|SCARE1|SLOX1 | |
| Cytomap | UCSC genome browser: 12p13.2-p12.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001172632.1, NM_001172633.1,NM_002543.3, | |
| Description | C-type lectin domain family 8 member AhLOX-1lectin-type oxidized LDL receptor 1ox LDL receptor 1oxidized low-density lipoprotein receptor 1oxidized low-density lipoprotein receptor 1, soluble formscavenger receptor class E, member 1 | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 602601 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000173391 | ||
| HPRD : 04003 | ||
| Vega : OTTHUMG00000168527 | ||
| Protein | UniProt: P78380 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_OLR1 | |
| BioGPS: 4973 | ||
| Pathway | NCI Pathway Interaction Database: OLR1 | |
| KEGG: OLR1 | ||
| REACTOME: OLR1 | ||
| Pathway Commons: OLR1 | ||
| Context | iHOP: OLR1 | |
| ligand binding site mutation search in PubMed: OLR1 | ||
| UCL Cancer Institute: OLR1 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for OLR1 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | F158 | S160L | HNSC | 1 | F158 | F158S | SKCM | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for OLR1 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | F158 | S160L | 0.37845037 | F158 | F158S | -1.0037946 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for OLR1 from PDB |
| Top |
| Differential gene expression and gene-gene network for OLR1 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for OLR1 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0027051 | Myocardial Infarction | 10 | Biomarker, GeneticVariation |
| umls:C0020538 | Hypertension | 5 | Biomarker, GeneticVariation |
| umls:C0878544 | Cardiomyopathies | 1 | Biomarker |
| umls:C0017661 | Glomerulonephritis, IGA | 1 | Biomarker |
| umls:C0018801 | Heart Failure | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for OLR1 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of OLR1 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | DIO | 1,4-DIOXANE | 1ypq | A | F158 |
| Top |
| Conservation information for LBS of OLR1 |
| Multiple alignments for P78380 in multiple species |
| LBS | AA sequence | # species | Species | D147 | APCPQDWIWHG | 1 | Homo sapiens | D147 | GPCPQDWLWHK | 1 | Mus musculus | D147 | GPCPQDWIWHK | 1 | Rattus norvegicus | D147 | GPCPQDWLWHE | 1 | Bos taurus | F158 | ENCYLF-HGPF | 2 | Mus musculus, Rattus norvegicus | F158 | ENCYLFSSGSF | 1 | Homo sapiens | F158 | ENCYQFSSGSF | 1 | Bos taurus | I149 | CPQDWIWHGEN | 1 | Homo sapiens | I149 | CPQDWLWHKEN | 1 | Mus musculus | I149 | CPQDWIWHKEN | 1 | Rattus norvegicus | I149 | CPQDWLWHEEN | 1 | Bos taurus | L157 | KENCYLF-HGP | 2 | Mus musculus, Rattus norvegicus | L157 | GENCYLFSSGS | 1 | Homo sapiens | L157 | EENCYQFSSGS | 1 | Bos taurus | Y197 | QQAISYSSFPF | 1 | Homo sapiens | Y197 | LQAISHTTSPF | 1 | Mus musculus | Y197 | LQATSHSTSPF | 1 | Rattus norvegicus | Y197 | QQMIAHSSFPF | 1 | Bos taurus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |